How to Medically Remove Water From Your Lungs

Removing water from the lungs involves a range of medical treatments, from intravenous medications that help your body flush the fluid naturally to physical drainage procedures where a doctor inserts a needle or tube to pull fluid out directly. The right approach depends heavily on where exactly the fluid has accumulated and what caused it to build up. These are not one-size-fits-all situations, and what works for heart-failure-related fluid looks very different from what works for an infection-related collection around the lung.

Where the Fluid Is Makes All the Difference

When people say “water in the lungs,” they could be describing two distinct problems that require different treatments. The first is pulmonary edema, where fluid leaks into the tiny air sacs inside the lung tissue itself, making it hard to exchange oxygen. This commonly happens when heart failure causes pressure to back up into the lungs, forcing fluid out of blood vessels and into spaces where air should be. The second is a pleural effusion, where fluid collects in the thin space between the lung and the chest wall. Infections, cancer, heart failure, and liver or kidney disease can all cause pleural effusions.

The distinction matters because pulmonary edema is typically treated with medications and breathing support, while pleural effusions often require physical drainage. Your doctor figures out which problem you have using chest X-rays, ultrasound, CT scans, and sometimes by analyzing a sample of the fluid itself. In some cases, both problems occur simultaneously, which means treatment addresses both fronts at once.

Medications That Help Your Body Clear the Fluid

For pulmonary edema caused by heart failure, intravenous loop diuretics like furosemide are the primary treatment. These drugs push your kidneys to produce far more urine than usual, pulling excess fluid out of your bloodstream and, by extension, reducing the pressure that forced fluid into the lungs in the first place.¹ In an emergency, this can work surprisingly fast. Doctors typically start with an IV dose and monitor your urine output closely over the following hours. If you don’t respond to the initial dose, they’ll increase it or sometimes combine two different types of diuretics to overcome resistance.

Vasodilators such as nitroglycerin are often used alongside diuretics, especially when high blood pressure is driving the edema. These medications relax blood vessels, reducing the workload on the heart and lowering the pressure pushing fluid into the lungs.² In acute cases, particularly with dangerously high blood pressure, doctors may use high-dose intravenous nitroglycerin as the primary intervention, with diuretics playing a supporting role. The combination works because each drug attacks a different part of the problem: diuretics reduce total fluid volume while vasodilators lower the pressure forcing that fluid where it shouldn’t be.

Breathing Support That Keeps You Off a Ventilator

When pulmonary edema is severe enough that your oxygen levels are dropping, doctors don’t just treat the fluid. They also support your breathing while the medications take effect. Non-invasive positive airway pressure, delivered through a mask rather than a tube down the throat, can be remarkably effective. The positive pressure does two useful things at once: it pushes open collapsed air sacs so oxygen can get through, and it actually reduces the amount of blood returning to the heart, which lowers the pressure driving fluid into the lungs.

Research shows that either continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) improves vital signs and reduces the need for intubation and hospital death compared to standard oxygen therapy alone.³ This matters a great deal to patients. Being intubated and placed on a mechanical ventilator carries serious risks, including infection, lung injury from the ventilator itself, and a longer stay in intensive care. Non-invasive breathing support serves as a bridge, keeping you stable while the diuretics and vasodilators do their work.

Draining Fluid With a Needle

When the problem is a pleural effusion rather than pulmonary edema inside the lung tissue, medications alone often aren’t enough. Thoracentesis is the most common drainage procedure: a doctor uses ultrasound to locate the fluid, numbs a spot on your back, and inserts a needle or small catheter between the ribs to drain the fluid directly. It sounds intimidating, but it’s performed routinely, often at the bedside, and most patients feel immediate relief as the fluid comes off and the lung re-expands.

Thoracentesis serves two purposes. The first is diagnostic: analyzing the drained fluid tells doctors whether the effusion is caused by infection, cancer, heart failure, or something else. The second is therapeutic: removing a large volume of fluid can dramatically improve breathing.⁴ Doctors typically don’t drain more than about 1,000 to 1,500 milliliters at a time. Removing too much too quickly increases the risk of re-expansion pulmonary edema, a paradoxical complication where the lung that was compressed by fluid suddenly fills with edema fluid as it re-inflates. A large analysis found that the risk of this complication increased by about 0.18% for every additional milliliter removed.⁵

Chest Tubes and Indwelling Catheters for Larger or Recurring Collections

When fluid accumulates rapidly, is too thick for a simple needle to drain, or keeps coming back, doctors move to more involved drainage methods. A chest tube is a larger tube inserted through the chest wall and connected to a drainage system, allowing continuous fluid removal over days. This is standard treatment for empyema (infected pleural fluid) and large effusions that need sustained drainage.

For patients whose effusions return repeatedly, especially those caused by cancer, an indwelling pleural catheter (IPC) offers a different strategy. This is a thin, flexible tube that stays in the chest long-term, with an external valve the patient or a caregiver can open at home to drain fluid as needed. IPCs are increasingly used for recurrent malignant pleural effusions, and in some cases for non-malignant effusions that resist other treatments.⁶ A trial comparing IPCs to traditional chest tube drainage with talc pleurodesis found that both strategies were highly effective at relieving breathlessness, with more than 75% of patients in each group achieving meaningful improvement and no significant difference in chest pain or quality of life between the two approaches.⁷

The trade-off is about lifestyle versus permanence. Talc pleurodesis (described below) aims to seal the space permanently so fluid can’t return, but it requires a hospital stay and a chest tube. An IPC lets you go home sooner but requires ongoing drainage at home, and it carries long-term risks including infection and catheter blockage.

Preventing Fluid From Coming Back

Draining fluid solves the immediate problem, but if the underlying cause persists, the fluid returns. Pleurodesis is a procedure designed to prevent that. After the fluid is drained, a chemical agent, most commonly sterile talc, is introduced into the pleural space. This triggers an inflammatory reaction that causes the two layers of the pleura to stick together, sealing the space so fluid can no longer accumulate.⁸ Pleurodesis is most commonly performed in patients with malignant effusions, where the cancer will continue producing fluid indefinitely if the space remains open.

For complicated parapneumonic effusions, where infection has caused the pleural fluid to become thick, sticky, and divided into pockets by fibrous strands, simply draining the fluid through a tube may not work well. Doctors can instill fibrinolytic agents such as streptokinase or alteplase directly into the pleural space through the chest tube. These medications break down the fibrous partitions, allowing trapped fluid to flow freely toward the drain.⁹ When used early in the course of the infection, intrapleural fibrinolytics reduce the likelihood of needing surgery and shorten hospital stays.¹⁰

Ultrafiltration When Diuretics Stop Working

Some patients with severe heart failure become resistant to diuretics. Their kidneys, damaged by years of poor circulation, simply stop responding to even high doses. When that happens, ultrafiltration offers an alternative way to remove fluid mechanically. The process is similar to dialysis: blood is drawn from a vein, passed through a filter that removes excess water and salt, and returned to the body. The key advantage is that it can remove fluid without depending on kidney function at all.¹¹

Ultrafiltration is generally reserved for patients who have failed aggressive diuretic therapy. It requires specialized equipment, vascular access through a large vein, and close monitoring, so it’s not a first-line option. But for the subset of heart failure patients whose congestion is genuinely unresponsive to medications, it can be a lifeline. The technique removes fluid more predictably than diuretics and, unlike high-dose diuretic combinations, doesn’t further stress already-compromised kidneys.

How Doctors Track Whether Treatment Is Working

Removing fluid from the lungs isn’t a one-shot event. Doctors monitor several indicators to know if treatment is succeeding and to catch fluid that starts creeping back. The most straightforward measures are body weight and fluid balance: if you’re losing weight and producing more urine than you’re taking in, the fluid is leaving. But these measures tell only part of the story.

Blood tests for natriuretic peptides, particularly a marker called NT-proBNP, are the most widely used tool for assessing congestion in heart failure, helping with diagnosis, risk assessment, and guiding treatment.¹² In hospitalized heart failure patients, reductions in NT-proBNP, weight loss, and net fluid loss have all been linked to better outcomes in the weeks after discharge. Specifically, each four-pound weight loss, each liter of net fluid removed, and each 10% drop in NT-proBNP were each independently associated with lower risk of death or rehospitalization within 60 days.¹³

Lung ultrasound has also emerged as a practical bedside tool. In patients undergoing hemodialysis, for example, the number of vertical lines visible on ultrasound (called B-lines) reflects the amount of extra fluid in the lungs. Patients whose B-line scores remained elevated after dialysis sessions were more likely to be hospitalized for pulmonary edema or acute cardiac events.¹⁴ The appeal of lung ultrasound is that it’s quick, radiation-free, and can be done at the bedside or in a clinic, making it useful for ongoing monitoring rather than just one-time diagnosis.

Non-Cardiogenic Pulmonary Edema and ARDS

Not all lung fluid stems from heart problems. In acute respiratory distress syndrome (ARDS), the tiny blood vessels in the lungs become leaky due to widespread inflammation, often triggered by pneumonia, sepsis, or severe trauma. The edema fluid in ARDS is different from what you see in heart failure: it contains far more protein, sometimes reaching 80 to 90% of the protein concentration in blood plasma, because the barrier between blood vessels and air sacs has broken down so thoroughly that large molecules pour through.¹⁵ This makes the fluid thicker and stickier, harder for the lungs to reabsorb on their own.

Treatment for ARDS focuses on supporting the patient while the underlying cause is treated. Mechanical ventilation with carefully controlled pressures keeps the lungs open and oxygenated. Diuretics are used cautiously to keep fluid balance in check, but the primary goal is to treat the infection, inflammation, or injury that caused the leak. You can’t simply “drain” ARDS edema the way you drain a pleural effusion, because the fluid is dispersed through millions of tiny air sacs rather than pooled in one accessible space. The lungs have to heal and reabsorb the fluid themselves, which takes days to weeks and doesn’t always happen completely.

When Medications Cause the Problem

A less obvious cause of lung fluid is the medications a person is already taking. A pharmacovigilance study analyzing adverse event reports identified 37 drugs significantly associated with drug-induced pulmonary edema. The drugs with the strongest associations included naloxone (an opioid reversal agent), dasatinib (a cancer drug), nifedipine (a blood pressure medication), and anti-thymocyte globulin (an immune suppressant).¹⁶ The list is strikingly diverse, spanning cancer treatments, heart medications, immune-suppressing drugs, and even commonly prescribed pain medications like fentanyl.

If you develop unexplained shortness of breath or signs of fluid buildup while on a new medication, drug-induced pulmonary edema is worth considering. It’s often missed because doctors naturally look for heart failure or infection first. The treatment is straightforward once it’s identified: stop the offending drug and provide supportive care while the fluid clears. The challenge lies in recognizing it, particularly in patients taking multiple medications for complex conditions, where any one of several drugs could be the culprit.

Surgical Options for Rare and Refractory Cases

Most patients never need surgery for fluid in their lungs. But when other approaches fail, several surgical options exist. Video-assisted thoracoscopic surgery (VATS) allows a surgeon to enter the chest through small incisions, break up fibrous tissue trapping fluid, and perform pleurodesis under direct vision. Open decortication, a more involved operation, strips away a thick rind of scar tissue that sometimes encases the lung after a prolonged infection, preventing the lung from fully expanding even after fluid is drained.

In rare situations involving chylothorax, where the thoracic duct leaks lymphatic fluid into the chest, specialized interventions come into play. Surgical ligation of the thoracic duct or percutaneous embolization to block the leak are options when conservative treatment fails. Surgical success rates for non-traumatic chylothorax are relatively modest at about 27%, whereas percutaneous thoracic duct embolization achieves better results, in the range of 50 to 67%.¹⁷ These are niche procedures for uncommon problems, but they illustrate the breadth of tools available when standard treatments fall short.

Newer Medications Changing Long-Term Management

For patients with chronic heart failure, the goal isn’t just to remove fluid during a crisis but to keep it from building up in the first place. A newer class of drugs called SGLT2 inhibitors, originally developed for diabetes, has shown striking benefits for heart failure patients. In a study of heart failure patients with reduced heart function, those who received an SGLT2 inhibitor alongside standard therapy saw a significant drop in estimated lung artery pressures, with the proportion of patients at high risk for pulmonary hypertension falling from 23% to 5%. Right heart function also improved meaningfully in the combination group.¹⁸

SGLT2 inhibitors work partly by promoting mild, sustained fluid loss through the kidneys, but their benefits extend well beyond simple diuresis. They appear to reduce the pressures that drive fluid into the lungs in the first place, which is a fundamentally different approach from waiting for fluid to accumulate and then removing it. For patients who have been through the cycle of hospitalization, aggressive diuresis, brief improvement, and rehospitalization, these drugs represent a shift toward preventing the crisis rather than just responding to it. They’ve become part of standard heart failure treatment guidelines, alongside older medications, and are one of the more genuinely encouraging developments in heart failure care in recent years.